Johnson & Johnson: Memory Disorders trials

The registry lists 11 Memory Disorders studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 3 8No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's DiseaseTerminatedNCT00679627Phase 3Results posted
• An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of GalantamineCompletedNCT00297414
• A Study of the Safety and Effectiveness of Galantamine Hydrobromide in Patients With Alzheimer's DiseaseCompletedNCT00297362
• A Survey Study of the Treatment and Outcome Management in Patients Diagnosed With Alzheimer's DiseaseCompletedNCT00291421
• A Study of the Safety and Effectiveness of a Flexible Dose of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253227Phase 3
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253201Phase 3
• A Study of the Safety and Effectiveness of Two Doses of Galantamine Versus Placebo in the Treatment of Patients With Alzheimer's DiseaseCompletedNCT00253188Phase 3
• A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive ImpairmentCompletedNCT00240695Phase 3
• A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentCompletedNCT00236574Phase 3
• A Study to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive ImpairmentCompletedNCT00236431Phase 3
• A Study of the Safety and Effectiveness of Galantamine in Patients With Alzheimer's DiseaseCompletedNCT00216502Phase 3